RecruitingNot ApplicableNCT03873259

Intraoperative Assessment of of Burst Wave Lithotripsy (BWL)

Burst Wave Lithotripsy (BWL) for the Comminution of Urinary Tract Stones: Intraoperative Evaluation of Safety and Effectiveness


Sponsor

University of Washington

Enrollment

40 participants

Start Date

Aug 8, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Burst Wave Lithotripsy (BWL) is a novel method of urinary stone fragmentation that uses multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. This is a single-arm feasibility study to test the ability of BWL to comminute (fragment) stones in humans.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Individuals presenting with at least one kidney stone apparent on CT
  • Individuals scheduled for clinical stone removal via ureteroscopy (URS)

Exclusion Criteria7

  • Individuals under 18 years of age
  • Individuals belonging to a vulnerable group (pregnant, mentally disabled, prisoner, etc.)
  • Individuals with uncorrected bleeding disorders or coagulopathies
  • Individuals taking a clinically significant anticoagulant dose at the time of the procedure
  • Individuals with a calcified abdominal aortic aneurysm or calcified renal artery aneurysm
  • Individuals with a solitary kidney
  • Individuals with a comorbidity risks which, at the discretion of the physician, would make the patient a poor candidate for the BWL procedure

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBurst Wave Lithotripsy

Fragment upper urinary tract stones


Locations(2)

IU Health North Hospital

Carmel, Indiana, United States

University of Washington Medical Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03873259


Related Trials